Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · people with cancer pain
Methadone may leads to higher participant‐reported pain intensity compared with morphine (low certainty).
1 finding from 1 review
Adverse events: appetite, thirst, somnolence · people with cancer pain
1 finding from 1 review
Moderate benefit: At least 30% reduction in pain, or PGIC much or very much improved · adults with chronic neuropathic pain
1 finding from 1 review
Substantial benefit: At least 50% reduction in pain, or PGIC much improved · adults with chronic neuropathic pain
1 finding from 1 review
Lack of efficacy withdrawal · adults with chronic neuropathic pain
1 finding from 1 review
Withdrawals due to adverse events · adults with chronic neuropathic pain
1 finding from 1 review
Participants experiencing anyserious adverseevents · adults with chronic neuropathic pain
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Deaths · adults with chronic neuropathic pain
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
CI: Confidence interval · adults with chronic neuropathic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dropout · opiate‐dependent pregnant women
Methadone showed no clear difference in dropout rate compared with buprenorphine (moderate certainty).
1 finding from 1 review
Birthweight (g) · opiate‐dependent pregnant women
1 finding from 1 review
APGAR score (APGAR score ) · opiate‐dependent pregnant women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events for the mother · opiate‐dependent pregnant women
1 finding from 1 review
Serious adverse events for the child · opiate‐dependent pregnant women
1 finding from 1 review
Use of Primary Substance · opiate‐dependent pregnant women
Methadone showed no clear difference in use of primary substance compared with buprenorphine (low certainty).
1 finding from 1 review
Birthweight (g) · opiate‐dependent pregnant women
1 finding from 1 review
APGAR scoreScale from: 0 to 10 · opiate‐dependent pregnant women
1 finding from 1 review
Number treated for NAS · opiate‐dependent pregnant women
Methadone showed no clear difference in number treated for NAS compared with buprenorphine (low certainty).
1 finding from 1 review
Proportion of mothers with serious adverse events ( · opiate‐dependent pregnant women
Methadone showed no clear difference in serious adverse events for the mother compared with buprenorphine (low certainty).
1 finding from 1 review
Serious adverse events for the child · opiate‐dependent pregnant women
Methadone showed no clear difference in serious adverse events for the child compared with buprenorphine (low certainty).
1 finding from 1 review